Ftse Mib
34.740,50
1,17%
DAX
18.799,78
0,64%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,00%
Bitcoin
63.316,44
0,44%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Geron Corp (GERN) Geron Corp (GERN) Notizie

GERN

Geron (GERN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GERN
DataOraFonteTitoloSimboloCompagnia
02/05/202413:00Business WireGeron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:GERNGeron Corp
25/04/202422:30Business WireGeron to Announce First Quarter 2024 Financial Results on May 2, 2024NASDAQ:GERNGeron Corp
18/04/202422:30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
03/04/202422:30Business WireGeron to Participate at Upcoming Investor Conferences in AprilNASDAQ:GERNGeron Corp
19/03/202414:07Business WireGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GERNGeron Corp
14/03/202420:54Business WireGeron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDSNASDAQ:GERNGeron Corp
28/02/202413:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
28/02/202413:05Business WireGeron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:GERNGeron Corp
16/02/202422:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
14/02/202423:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GERNGeron Corp
14/02/202422:30Business WireGeron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:GERNGeron Corp
12/01/202414:30Business WireGeron to Participate in the B. Riley Securities Virtual Oncology ConferenceNASDAQ:GERNGeron Corp
11/12/202322:15Business WireGeron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDSNASDAQ:GERNGeron Corp
06/12/202314:00Business WireGeron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory MyelofibrosisNASDAQ:GERNGeron Corp
04/12/202311:00Business WireGeron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDSNASDAQ:GERNGeron Corp
28/11/202322:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GERNGeron Corp
28/11/202314:00Business WireGeron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of DirectorsNASDAQ:GERNGeron Corp
07/11/202322:30Business WireGeron to Participate at Upcoming Investor Conferences in NovemberNASDAQ:GERNGeron Corp
02/11/202322:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GERNGeron Corp
02/11/202314:00Business WireGeron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDSNASDAQ:GERNGeron Corp
02/11/202313:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GERNGeron Corp
02/11/202313:00Business WireGeron Corporation Reports Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:GERNGeron Corp
26/10/202322:30Business WireGeron to Announce Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:GERNGeron Corp
29/09/202314:00Business WireGeron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDSNASDAQ:GERNGeron Corp
28/09/202301:32Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:GERNGeron Corp
12/09/202315:23IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:GERNGeron Corp
11/09/202322:30Business WireGeron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial OfficerNASDAQ:GERNGeron Corp
07/09/202314:00Business WireGeron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual MeetingNASDAQ:GERNGeron Corp
05/09/202322:30Business WireGeron to Participate in the Baird 2023 Global Healthcare ConferenceNASDAQ:GERNGeron Corp
22/08/202314:00Business WireGeron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDSNASDAQ:GERNGeron Corp
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GERN

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BFF
BFF Bank
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
MB
Mediobanca Banca di Cred...
BIT
BAMI
Banco BPM
BIT
G
Generali
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network